Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide for Bile Reflux in Roux-en-Y Patients
NCT02054637Phase 2Unknown
- Sponsor
- UZ Brussel
- Start
- Apr 2014
- Primary completion
- Dec 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lanreotide in reflux esophagitis, sponsored by UZ Brussel. Primary endpoint: Los Angeles criteria for reflux esophagitis at 12 weeks. Status: unknown.
02
Drugs
lanreotide
03
Conditions
reflux esophagitis
Beyond the preview
Go deeper on NCT02054637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02054637.